Standard BioTools Inc. Lease, Cost
Standard BioTools Inc. (LAB) reported Lease, Cost of $7.84 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-16
- Standard BioTools Inc. lease, cost for the quarter ending 2024-12-31 was -$327.00K, a 116.06% decline year-over-year.
- Standard BioTools Inc. lease, cost for the quarter ending 2024-09-30 was $2.50M, a 8.85% increase year-over-year.
- Standard BioTools Inc. lease, cost for the quarter ending 2024-06-30 was $2.86M, a 24.79% increase year-over-year.
- Standard BioTools Inc. lease, cost for the quarter ending 2024-03-31 was $2.67M, a 44.28% increase year-over-year.
- Standard BioTools Inc. lease, cost for fiscal 2025 was $7.84M, a 1.66% increase from fiscal 2024.
- Standard BioTools Inc. lease, cost for fiscal 2024 was $7.71M, a 9.08% decline from fiscal 2023.
- Standard BioTools Inc. lease, cost for fiscal 2023 was $8.48M, a 20.95% decline from fiscal 2022.
- Standard BioTools Inc. lease, cost for fiscal 2022 was $10.73M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $7.84M 10-K · filed 2026-03-16 | ||||
| 2024-12-31 | -$327.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.17M derived: sum of 2 quarters · filed 2026-03-16 | $5.04M derived: sum of 3 quarters · filed 2026-03-16 | $7.71M 10-K · filed 2026-03-16 | $10.57M 10-K · filed 2025-03-11 |
| 2024-09-30 | $2.50M 10-Q · filed 2024-11-06 | $5.36M derived: sum of 2 quarters · filed 2024-11-06 | $8.04M 10-Q · filed 2024-11-06 | $10.07M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-06-30 | $2.86M 10-Q · filed 2024-08-06 | $5.54M 10-Q · filed 2024-08-06 | $7.58M derived: sum of 3 quarters · filed 2026-03-16 | $9.87M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-03-31 | $2.67M 10-Q · filed 2024-05-09 | $4.71M derived: sum of 2 quarters · filed 2026-03-16 | $7.01M derived: sum of 3 quarters · filed 2026-03-16 | $9.30M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2023-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $4.33M derived: sum of 2 quarters · filed 2026-03-16 | $6.63M derived: sum of 3 quarters · filed 2026-03-16 | $8.48M 10-K · filed 2026-03-16 | |
| 2023-09-30 | $2.29M 10-Q · filed 2024-11-06 | $4.59M derived: sum of 2 quarters · filed 2024-11-06 | $6.44M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $2.29M 10-Q · filed 2024-08-06 | $4.15M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $1.85M 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | $10.73M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |